Metropolis Healthcare Board Meeting Scheduled on May 13, 2026 to Approve FY26 Results and Consider Interim Dividend

Metropolis Healthcare has notified the stock exchanges of a scheduled Board of Directors meeting on Wednesday, May 13, 2026, pursuant to Regulation 29 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The intimation, referenced as MHL/Sec&Legal/2026-27/05 and dated May 07, 2026, was addressed to both BSE Limited and the National Stock Exchange of India Ltd.

Key Agenda Items

The board meeting has been convened to address two primary items. The following table outlines the key agenda for the upcoming meeting:

Agenda Item:	Details
Financial Results:	Consider and approve audited standalone and consolidated financial results for the quarter and financial year ended March 31, 2026
Dividend Consideration:	Consider declaration of 2nd interim dividend, if any, on equity shares for the financial year 2025-26
Meeting Date:	Wednesday, May 13, 2026
Regulatory Reference:	Regulation 29 of SEBI (LODR) Regulations, 2015

Trading Window Closure

In accordance with the Company's Code of Conduct for Prevention of Insider Trading, the Trading Window for dealing in the securities of the company has been closed from April 01, 2026, to May 15, 2026 (both days inclusive). This restriction applies to all designated persons and is a standard compliance measure ahead of the announcement of financial results.

The intimation was signed by Kamlesh C Kulkarni, Head – Legal & Secretarial, on behalf of Metropolis Healthcare Limited.

1 Day	5 Days	1 Month	6 Months	1 Year	5 Years
+8.68%	+15.32%	+26.50%	+11.92%	+29.63%	-3.41%

Metropolis Healthcare Limited has submitted its quarterly compliance certificate to stock exchanges for the quarter ended March 31, 2026, fulfilling regulatory requirements under SEBI (Depositories and Participants) Regulations, 2018. The filing, dated April 07, 2026, confirms the company's adherence to prescribed dematerialisation processes and securities handling procedures.

Regulatory Compliance Certificate

The certificate was issued by MUFG Intime India Private Limited, formerly known as Link Intime India Private Limited, which serves as the company's Registrar and Transfer Agent. This document specifically addresses compliance with Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018, covering the quarter ended March 31, 2026.

Parameter	Details
Filing Date	April 07, 2026
Quarter Covered	Q4FY26 (ended March 31, 2026)
Registrar	MUFG Intime India Private Limited
Reference Number	MHL/Sec&Legal/2026-27/02

Dematerialisation Process Confirmation

The registrar confirmed that all securities received from depository participants for dematerialisation during the quarter were properly processed within prescribed timelines. The certificate validates that securities received for dematerialisation were appropriately confirmed or rejected to the depositories, with proper substitution of depository names in the member register.

Key aspects of the compliance confirmation include:

Proper handling of securities received for dematerialisation
Timely confirmation or rejection to depositories
Appropriate mutilation and cancellation of physical certificates
Substitution of depository names as registered owners within prescribed timelines

Filing Details and Authorization

The submission was authorized by Kamlesh C Kulkarni, Head – Legal & Secretarial at Metropolis Healthcare Limited, with digital signature authentication completed on April 07, 2026. The certificate from MUFG Intime India was signed by Ashok Shetty, Sr. Vice President-Corporate Registry, dated April 01, 2026.

This quarterly filing represents standard regulatory compliance for listed companies, ensuring transparency in securities handling and maintaining investor confidence in the dematerialisation process. The certificate confirms that all securities transactions during Q4FY26 were conducted in accordance with SEBI regulations and established market practices.